Programmable Cell Therapy

Scroll

ArsenalBioCellTherapy CloudComputing ComputationalBiology GenomeEngineering MachineLearning SoftwareEngineering SyntheticImmunology

ArsenalBio was founded to discover, develop and commercialize curative immune cell therapies

Board of Directors

Brook Byers

Ken Drazan MD

Matt Fust

Valentin Barsan MD

Sean Parker

Beth Seidenberg MD

Board Observers

Alexander Marson MD PhD

Ryan Sublett

Wolfgang Seibold

Leadership Team

Ken Drazan MD
Chairman, CEO, Co-founder

Susie Jun MD PhD
Chief Medical Officer

Tarjei Mikkelsen PhD
Chief Technology Officer

Bee Nguyen
Chief People Officer

Tim Sirichoke
Chief Technical Operations Officer

W. Nicholas Haining BM BCh
Chief Scientific Officer

Irene Pleasure, PhD, JD
General Counsel & Corporate Secretary

Science Founders

Brad Bernstein MD PhD

W. Nicholas Haining BM BCh

Alexander Marson MD PhD

Theo Roth MD PhD

Kole T. Roybal PhD

E. John Wherry PhD

Scientific Advisors

Howard Y. Chang PhD

Ananda Goldrath PhD

Cameron Turtle MBBS PhD

Special Advisors

Barbara Kosacz

Investors

News

May 16, 2023 / ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting /

Apr 14, 2023 / ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable Cell Therapy Progress /

Jan 5, 2023 / ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian Cancer /

Sep 27, 2022 / Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology /

Sep 6, 2022 / Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development /

Jun 2, 2022 / Arsenal Biosciences to Present at the 2022 Jefferies Healthcare Conference /

Jan 27, 2022 / Computational Biology's Effect On Solid Tumors /

Jan 10, 2022 / ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors /

Jan 3, 2022 / ArsenalBio to Present at J.P. Morgan Healthcare Virtual Conference 2022 /

Nov 19, 2021 / ArsenalBio to Participate in Upcoming Investor Conferences /

Nov 4, 2021 / ArsenalBio Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting /

October 12, 2021 / Winners of the 3rd Annual UCSF Health Awards Announced at Grand Finale at the Chase Center at Mission Bay in San Francisco. /

Sept 8, 2021 / ArsenalBio to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference /

July 19, 2021 / ArsenalBio Strengthens Leadership Team with the Appointment of W. Nicholas Haining, BM, BCh, as Chief Scientific Officer Paradigm to Discover and Develop Immune Cell Therapies /

Mar 8, 2021 / ArsenalBio Announces Appointment of John Schroer as Chief Financial Officer and Tim Sirichoke as Chief Technical Operations Officer /

Jan 7, 2021 / ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors. /

Oct 17, 2019 / ArsenalBio Launches With $85 Million Series A Financing to Advance New Paradigm to Discover and Develop Immune Cell Therapies /